Sequelae and survivorship in patients treated with (131)I-MIBG therapy

BACKGROUND: (131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. Newer treatment modalities are emerging for neuroendocrine tumours (NETs) and chromaffin cell tumours (CCTs), but many of these do not yet have adequate long-term follow-up to determine their longer te...

Descripción completa

Detalles Bibliográficos
Autores principales: Sze, W C C, Grossman, A B, Goddard, I, Amendra, D, Shieh, S C C, Plowman, P N, Drake, W M, Akker, S A, Druce, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738119/
https://www.ncbi.nlm.nih.gov/pubmed/23860527
http://dx.doi.org/10.1038/bjc.2013.365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738119/
https://www.ncbi.nlm.nih.gov/pubmed/23860527
http://dx.doi.org/10.1038/bjc.2013.365

Ejemplares similares